Policy and Governance Structure

Policy and Governance Structure

JCR has been committed to advancing biotechnology, cell therapy, and regenerative medicine to develop transformative treatments for rare diseases and other unmet medical needs.

As global environmental and social challenges evolve, so too does our responsibility as a pharmaceutical innovator. We view sustainability not as an add-on, but as an integral part of our mission. Our focus spans four key areas: Rare Diseases, Environment, Society, and Corporate Governance—with rare diseases at the heart of everything we do.

Even in areas of ultra-rare conditions where patient numbers are extremely small, we pursue what only JCR can achieve to build a future where no one is left behind.

Driving Sustainability from Within

To address evolving societal and environmental challenges, JCR established three cross-functional committees in July 2022—Sustainability Advisory Committee, Sustainability Committee, and Environmental Committee.

Sustainability Advisory Committee

Provides guidance to the Board on sustainability matters, with members including internal and independent external directors and executive officers.

Sustainability Committee

Led by the sustainability officer and composed of cross-functional members, this committee identifies materiality, oversees ESG initiatives, tracks progress, and reports to the Board.

Environmental Committee

Composed of internal directors and selected employees, the committee promotes sustainable practices and identifies environmental risks to our long-term business.